AUSTRALIAN scientists believe they have found a way to stunt the growth of melanoma by cutting off its food supply.
The idea is to prevent the amino acid glutamine from entering the melanoma cells, say the scientists from the University of Sydney and the Centenary Institute.
Amgen and Merck announced they have entered into an agreement through a subsidiary to evaluate the safety and efficacy of talimogene laherparepvec, an investigational oncolytic immunotherapy, combined with MK-3475, an investigational anti-PD-1 immunotherapy, in a Phase 1b/2 study of patients with mid- to late-stage melanoma.
Galectin Therapeutics has announced that the US Food and Drug Administration (FDA) has agreed that a Phase IB clinical trial of the galectin inhibitor GR-MD-02 in combination with Yervoy (ipilimumab) in patients with metastatic melanoma may proceed.
GlaxoSmithKline has reported headline results of a Phase III trial of the Tafinlar (dabrafenib)-Mekinist (trametinib) combination, compared to single agent therapy with Tafinlar in patients with BRAF V600 E or K mutation positive unresectable or metastatic melanoma.
